The efficacy of chimeric vaccines constructed with PEP-1 and Ii-Key linking to a hybrid epitope from heterologous viruses

Basha, 2012, A CD74-dependent MHC class I endolysosomal cross-presentation pathway, Nat Immunol, 13, 237, 10.1038/ni.2225 Walline, 2014, Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy, Immunology, 141, 531, 10.1111/imm.12210 Beyan, 2008, Study of T cell response to Ii-Key/MHC class II epitope hybrids in human type 1 diabetes, Diabetes, 57, A18 Holmes, 2008, Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine, J Clin Oncol, 26, 3426, 10.1200/JCO.2007.15.7842 Mikkelsen, 2011, Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain, J Immunol, 86, 2355, 10.4049/jimmunol.1001877 Xu, 2012, CD4+T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines, Vaccine, 30, 2805, 10.1016/j.vaccine.2012.02.031 Perez, 2014, Invariant chain-peptide fusion vaccine using HER-2/neu, Methods Mol Biol, 1139, 321, 10.1007/978-1-4939-0345-0_26 Adams, 1997, Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC II molecules, Arzneimittelforschung, 47, 1069 Chamuleau, 2004, Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome, Cancer Res, 64, 5546, 10.1158/0008-5472.CAN-04-1350 Morris, 2001, Peptide carrier for the delivery of biologically active proteins into mammalian cells, Nat Biotechnol, 19, 1173, 10.1038/nbt1201-1173 Jeong, 2014, Down-regulation of MAPK/NF-kappa KB signaling underlies anti-inflammatory response induced by transduced PEP-1–Prx2 proteins in LPS-induced raw 264.7 and TPA-induced mouse ear edema model, Int Immunopharmacol, 23, 426, 10.1016/j.intimp.2014.09.008 Kim, 2015, The effects of PEP-1–FK506BP on dry eye disease in a rat model, BMB Rep, 48, 153, 10.5483/BMBRep.2015.48.3.123 An, 2008, Transduction of familial amyotrophic lateral sclerosis-related mutant PEP-1–SOD proteins into neuronal cells, Mol Cells, 25, 55 Kim, 2012, PEP-1–p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression, BMB Rep, 45, 532, 10.5483/BMBRep.2012.45.9.083 Zhang, 2009, In vivo protein transduction: delivery of PEP-1–SOD1 fusion protein into myocardium efficiently protects against ischemic insult, Mol Cells, 27, 159, 10.1007/s10059-009-0020-4 Wang, 2005, Identification of neutralizing epitopes on the VP2 protein of infectious bursal disease virus by phage-displayed heptapeptide library screening and synthetic peptide mapping, Viral Immunol, 18, 549, 10.1089/vim.2005.18.549 Chammbers, 1988, Location of a neutralizing epitope for the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus, J Gen Virol, 69, 2115, 10.1099/0022-1317-69-8-2115 Biji, 2011, An overview of western blotting for determining antibody specificities for immunohistochemistry, Methods Mol Biol, 717, 56 Alinari, 2012, Novel targeted therapies for mantle cell lymphoma, Oncotarget, 3, 203, 10.18632/oncotarget.426 Gupta, 2012, Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas, Blood, 119, 3767, 10.1182/blood-2011-09-381988 Holst, 2008, MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines, Immunol, 180, 3339, 10.4049/jimmunol.180.5.3339 Xu, 2009, Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers, Vaccine, 27, 4641, 10.1016/j.vaccine.2009.05.054 Kim, 2008, Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun, J Immunol, 180, 7019, 10.4049/jimmunol.180.10.7019 Walchli, 2014, Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation, Eur J Immunol, 44, 774, 10.1002/eji.201343671 Perez, 2010, Results from a phase I clinical study of the novel Ii-Key/HER-2/neus(776–790) hybrid peptide vaccine in patients with prostate cancer, Clin Cancer Res, 16, 3495, 10.1158/1078-0432.CCR-10-0085 Voutsas, 2007, Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain, Int J Cancer, 121, 2031, 10.1002/ijc.22936 Gillogly, 2004, Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer, Cancer Immunol Immunother, 53, 490, 10.1007/s00262-003-0463-y An, 2008, Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult, FEBS J, 275, 1296, 10.1111/j.1742-4658.2008.06291.x Jeong, 2014, Neuroprotective effect of PEP-1–peroxiredoxin2 on CA1 regions in the hippocampus against ischemic insult, Biochim Biophys Acta, 1840, 2321, 10.1016/j.bbagen.2014.03.003 Ding, 2012, Molecular interactions between cell penetrating peptide Pep-1 and model cell membranes, J Phys Chem B, 116, 2545, 10.1021/jp209604m Chen, 2012, Boosting immune response with the invariant chain segments via association with non-peptide binding region of major histocompatibility complex class II molecules, BMC Immunol, 13, 55, 10.1186/1471-2172-13-55 Kallinteris, 2005, Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48–58) MHC class II epitope, J Immunother, 28, 352, 10.1097/01.cji.0000170362.45456.00